

In vivo radioadaptive response: A review of studies relevant to radiation-induced cancer risk

M Neno, B Wang and G Vares

Abstract

Radioadaptive response (RAR) describes phenomena where small conditioning doses of ionizing radiation (IR) reduce detrimental effects of subsequent higher IR doses. Current radiation protection regulations do not include RAR because of the large variability in expression among individuals and uncertainties of the mechanism. However, RAR should be regarded as an indispensable factor for estimation and control of individual IR sensitivity. In this article, RAR studies relevant to individual cancer risk are reviewed. Using various stains of mice, carcinogenic RAR has been demonstrated. Consistently much *in vivo* evidence for RAR with end points of DNA and chromosome damage is reported. Most *in vivo* RAR studies revealed efficient induction of RAR by chronic or repeated low-dose priming irradiation. Chronic IR-induced RAR was observed also in human individuals after environmental, occupational, and nuclear accident radiation exposure. These observations may be associated with an intrinsically distinct feature of *in vivo* experimental systems that mainly consist of nonproliferating mature cells. Alternatively, induction of RAR by gap junction-mediated bystander effects suggests that multicellular systems comprising densely communicating cells may be capable of responding to long-lasting low-dose-rate priming irradiation. Regulation by endocrine factors is also a plausible mechanism for RAR at an individual level. Emerging evidence suggests that glucocorticoids, known as stress hormones, participate in *in vivo* RAR induction following long-term low-dose-rate exposure to IR.

Keywords

Radioadaptive response, low-dose-rate radiation, intercellular signal transduction, protective bystander effect, endocrine regulation

Introduction

It is widely accepted that ionizing radiation (IR) at high doses is detrimental to the exposed organism. However, biological effects of low-dose or low-dose-rate IR remain elusive. Radioadaptive response (RAR) is a term describing phenomena where a small conditioning dose of IR (called the ‘priming dose’) reduces the biological effects of subsequent higher doses of IR (called the ‘challenge dose’). Since its discovery by Olivieri et al.¹ in 1984, RAR has been confirmed using a variety of experimental systems ranging from yeasts to animal models. The end points are such effects as IR-induced DNA damage, chromosomal aberrations, cell transformation, cell death, and mutation in *in vitro* experiments and prenatal death, malformation, hematopoietic death, and carcinogenesis in *in vivo* experiments.² Keen interest has been shown

in RAR with the end points of carcinogenesis and the related genomic damage because IR-induced cancer is a major concern in the risk assessment of low-dose or low-dose-rate IR.

There is considerable interindividual variation in the expression of RAR. In a study analyzing RAR in human lymphocytes from numerous individuals, it was reported that RAR with the end points of chromatid or chromosome damage was observed in

Research Center for Radiation Protection, National Institute of Radiological Sciences, Inage-ku, Chiba, Japan

Corresponding author:

M Neno, Research Center for Radiation Protection, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.

Email: m_neno@nirs.go.jp

50–78% of cases, and its extent (magnitude of reduction of challenge dose effects after priming dose exposure) ranged from 11% to 32%.³ A genetic constitution is thought to be the major source of the interindividual variability because the interindividual difference is not considerable in monozygotic twins, whereas dizygotic twins show greater variability.⁴ Due to the large variability between individuals as well as uncertainties of the mechanism, the International Commission on Radiation Protection concluded that RAR should not be included in the estimation of the potential risk to human population for low-level IR exposure.⁵ However, RAR could potentially modulate the IR sensitivity of some fraction of individuals so remarkably that it should be regarded as an indispensable factor in “tailor-made radiation protection,” which is a prospective radiation protection system based on estimation and control of the IR sensitivity of individuals.

Progress in RAR research in the last three decades has been well reviewed in several articles.^{2,3,6–9} Here, we focus on the studies of RAR investigated at the individual level with a particular interest in a possible link to cancer risk. RAR studies in which challenge irradiation was carried out *in vitro* are included in the scope of this review if RAR was induced *in vivo* by irradiating individuals with priming doses. However, RAR studies irrelevant to cancer risks are not included. A significant mechanistic role of intercellular signaling such as bystander effects and endocrine signal transduction through hormones in RAR is discussed with a particular emphasis on its implication in risk modulation by low-dose-rate IR.

Evidence of *in vivo* RARs

Animal data

Animal models showing *in vivo* RAR have been reported from several groups as summarized in Table 1. Carcinogenic RAR was first demonstrated by Bhattacharjee,¹⁰ who observed that the yield of thymic lymphoma of Swiss mice induced by 2 Gy of γ rays was remarkably decreased when the mice were preirradiated with a priming dose of 10 mGy day⁻¹ for 5 or 10 consecutive days. Ina et al.¹¹ reported that induction of thymic lymphomas by four fractionated doses of 1.8 Gy each (7.2 Gy in total) in C57BL/6 mice was suppressed consistently by preirradiation with 75 mGy of X-rays given 6 h before each 1.8 Gy irradiation. They also showed that induction of thymic lymphomas was more effectively suppressed by continuous whole-body

irradiation with γ rays at 1.2 mGy h⁻¹ for 450 days starting 35 days before the challenge dose of irradiation. It is interesting that chronic exposure or fractionated low-dose IR has efficiently suppressed carcinogenesis induced by the challenge dose. Modulation of cancer development through *in vivo* RAR has been observed in a variety of mouse strains. Mitchel et al.¹² reported that the latent period for development of acute myeloid leukemia induced by a challenge dose of 1 Gy in CBA/Harwell mice was significantly increased when the mice were preirradiated with a 100-mGy priming dose 24 h prior to the challenge dose. Mitchel et al.²⁷ also reported that a single exposure of either 10 or 100 mGy alone reduced spontaneous cancer development in p53 heterozygous mice. Kakinuma et al.¹³ reported that four deliveries (1 week⁻¹) of a fractionated dose of 200 mGy (800 mGy in total) suppressed *N*-ethyl-*N*-nitrosourea-induced thymic lymphoma in B6C3F1 mice, suggesting a mechanism for RAR against chemical carcinogenesis.

Induction of genomic damage is thought to be a critical step in IR carcinogenesis. Consistent with the above-mentioned carcinogenic RAR, much data for *in vivo* RAR with the end point of genomic damage, such as chromosomal aberrations, micronuclei induction, DNA double-strand breaks (DSBs), and gene mutations in lymphocytes or other somatic cells have been reported (Table 1).^{17–23} For example, Otsuka et al.²² analyzed DNA damage in spleen of C57BL/6N mice by a comet assay and revealed that DNA damage induced by a 0.4-Gy challenge dose was significantly reduced in the mice that had been preirradiated at 1.2 mGy h⁻¹ for 23 days (500 mGy in total) compared with that in the sham-irradiated mice. The authors further revealed a correlation between reduced DNA damage and induction of antioxidative enzymes in the RAR condition. Induction of RAR by extremely low doses of X-rays was demonstrated in transgenic mice. By conducting a chromosomal inversion assay in the pKZ1 mouse, which contains the β -galactosidase gene in inverse orientation with respect to the β -actin promoter, Day et al.²¹ showed that 0.001–10 mGy followed 4 h later by a 1-Gy challenge dose caused reduction in inversions in prostates compared with those in mice irradiated with 1 Gy alone. Recently, *in vivo* RAR was explored using IR sources of high public concern such as nuclear medicine diagnostic devices and environmental radionuclides released from nuclear accidents. Phan et al.²⁴ irradiated C57BL/6 mice with X-rays from a computed tomography (CT) scanner followed by irradiation of bone marrow cells withdrawn from the mice with a

Table 1. In vivo RAR studies using animal models with the carcinogenic or related end points.

Animal model	Priming dose			Challenge dose			Time interval	End point remarks	Reference
	Radiation	Dose	Radiation	Radiation	Dose				
Swiss mouse	γ Rays	10 mGy day ⁻¹ × 5–10 days	γ Rays	γ Rays	2 Gy	24 h	Thymic lymphoma	10	
C57BL/6 mouse	X-Rays	75 mGy given before each 1.8 Gy dose	X-Rays	X-Rays	1.8 Gy week ⁻¹ × 4 weeks	6 h	Thymic lymphomas	11	
C57BL/6 mouse	γ Rays	Continuous 1.2 mGy h ⁻¹ × 450 days	X-Rays	X-Rays	1.8 Gy week ⁻¹ × 4 weeks	–	Thymic lymphomas	11	
CBA/Harwell mouse	γ Rays	100 mGy (500 mGy h ⁻¹)	γ Rays	γ Rays	1 Gy	24 h	Latent period for acute myeloid leukemia	12	
B6C3F1 mouse	X-Rays	200 mGy week ⁻¹ × 4 weeks	ENU	ENU	50–200 ppm	3 days	Thymic lymphomas	13	
ICR mouse	900 MHz radiofrequency	120 W cm ⁻² × 4 h day ⁻¹ × 1–14 days	γ Rays	γ Rays	3 Gy	4 h	DNA damage (comet tail length) in peripheral leukocytes	15	
ICR mouse	900 MHz radiofrequency	120 W cm ⁻² × 4 h day ⁻¹ × 7 days	γ Rays	γ Rays	3 Gy	4 h	MN induction in immature erythrocytes	41	
C57BL/6 transgenic mouse	NNK	2 mg day ⁻¹ × 4 days in the middle course of challenge irradiation	γ Rays	γ Rays	1.5 mGy h ⁻¹ × 31 days	–	Chromosomal large deletion (>1 kb) in lung	16	
rabbit	γ Rays	0.3–1.8 Gy (5.6 mGy h ⁻¹)	X-Rays	X-Rays	1.5 Gy	6–38 days	Chromosomal aberrations in peripheral blood lymphocytes	17	
Kunming mouse	X-Rays	10 mGy (3.0 Gy h ⁻¹)	X-Rays	X-Rays	0.75 Gy	2.5–3 h	Chromatid aberrations in bone marrow cells and spermatocytes	18	
C57BL/6 mouse	X-Rays	2–100 mGy (3.0 Gy h ⁻¹)	X-Rays	X-Rays	0.65 Gy	2.5–3 h	Chromatid aberrations in bone marrow cells	18	
Af mouse	X-Rays	200 mGy (3.4 Gy h ⁻¹)	X-Rays	X-Rays	1.5 Gy	4 h	Chromosomal aberrations in bone marrow cells	19	
C57BL/6 transgenic mouse	X-Rays	150–375 mGy (over 3 days)	X-Rays	X-Rays	2.5 Gy	3 weeks	lacZ mutation in brain	20	

(continued)

Table 1. (continued)

Animal model	Priming dose		Challenge dose		Time interval	End point remarks	Reference
	Radiation	Dose	Radiation	Dose			
C57BL/6 transgenic mouse	X-Rays	Acute 0.001–10 mGy	X-Rays	1 Gy	4 h	Chromosome inversions at lacZ locus in prostate	21
C57BL/6 mouse	γ Rays	500 mGy (1.2 mGy h ⁻¹)	X-Rays	0.4 Gy	23 days	DNA damage in spleen analyzed by comet assay	22
C57BL/6 mouse	X-Rays	Acute 500 mGy	X-Rays	7.5 Gy	2 weeks	MN induction in polychromatic and normochromatic erythrocytes	23
C57BL/6 mouse	X Rays	Acute 500 mGy	Heavy particles	5.5–5.75 Gy	2 weeks	MN induction in polychromatic and normochromatic erythrocytes	23
C57BL/6 mouse	X Rays from CT scanner	2 × 20 mGy week ⁻¹ × 10 weeks	γ Rays	1–2 Gy	5 days	γ H2AX in lymphocyte-rich population of bone marrow cells	24
BALB/c mouse fetus	Chernobyl soils	10–13 mSv day ⁻¹ for 10 days during organogenesis	γ Rays	2.4 Sv	After born and weaned	MN induction in polychromatic erythrocytes	25
SHK white mongrel mouse	BH and protons	160 mGy (4.3 mGy day ⁻¹)	X-Rays	1.5 Gy	One to two generations	MN induction in bone marrow cells of F ₁ and F ₂ offsprings	33
Leopard frog	β Rays	Approximately 1 mGy year ⁻¹	γ Rays	4 Gy	–	Chromosome breaks in liver cells	9
Leopard frog	γ Rays	(Chronic) 1–100 mGy	γ Rays	4 Gy	–	Chromosome breaks in liver cells	9

RAR: radioadaptive response; ENLU: N-ethyl-N-nitrosourea; NNK: 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; BH: bendazol hydrochloride; MN: micronulei.

1–2-Gy challenge dose. They found an approximately 10% decrease in γ H2AX fluorescence level in bone marrow cells from the repeatedly CT-scanned mice (irradiation with 20 mGy twice a week for 10 consecutive weeks) compared with that in sham CT-scanned mice. The authors pointed out a requirement of repeated CT scans to confer resistance to the challenge dose because no RAR could be observed in mice receiving only a single CT scan. Howell et al.²⁵ used an exposure plate comprised of soils collected from contaminated areas in Chernobyl, mainly containing cesium-137 and strontium-90. Pregnant BALB/c mice were irradiated on the exposure plate at 10–13 mSv d⁻¹ for 10 days during organogenesis in the mouse fetus. The progeny mice born from the irradiated or sham-irradiated pregnant mice were exposed to the challenge dose of 2.4 Sv of γ rays after weaning. As a result, decreased micronuclei induction was observed in polychromatic erythrocytes from mice preirradiated with IR from Chernobyl soils.

It should be noted that the majority of *in vivo* RAR studies revealed efficient suppression of IR-induced carcinogenesis or genomic damage by chronic or repeated low-dose priming irradiation. This is a distinguishing feature of *in vivo* RAR observations compared with those of *in vitro* studies, although there are a few reports that describe induction of RAR in cultured cells by priming doses delivered at marginally low-dose-rates such as 300 mGy h⁻¹.²⁸ The difference may be attributable to the technical difficulties inherent in *in vitro* experiments to irradiate cultured cells or tissues with chronic or fractionated low-dose IR. Alternatively, it may be related to an intrinsically distinct feature of *in vivo* experimental systems. Two aspects can be considered. The first is that the *in vivo* experimental systems consist of a majority of nonproliferating mature cells, which are more likely capable of spending a long time to accumulate enough priming stimuli to induce RAR. Besides, whereas the repair of IR-induced DNA damage is thought to play an important role in RAR,^{29–32} different DSB repair pathways are chosen depending on the cell cycle.²⁶ It may be speculated that the DSB repair pathway in nonproliferating cells is differently induced by low-dose-rate priming irradiation. The second aspect to consider is that the cells in *in vivo* experimental systems are aligned in a three-dimensional structure and are associated with neighboring cells through a distinct intercellular communication different from that of cells in two-dimensional *in vitro* experimental

systems. A highly organized multicellular structure composed of densely communicating cells could respond to low-dose-rate priming irradiation even if only a minor fraction of the structure is irradiated at any moment. The cells in *in vivo* experimental systems are also likely to be under the control of systemic endocrine regulation. Intercellular dense communication within multicellular systems, and/or long-term hormonal regulation, is the plausible mechanism for *in vivo* RAR after chronic or sporadic low-dose priming irradiation.

There is one *in vivo* study that described transgenerational transmission of RAR-induced radioresistance. Sorokina et al.³³ observed that the combined exposure of SHK white mongrel male mice to the immunomodulator bendazol hydrochloride and 160 mGy of chronic protons reduced micronuclei induction in bone marrow cells of F₁ and F₂ offsprings irradiated with the challenge dose (1.5 Gy) of X-rays. Although genetic effects of IR have not been observed in humans, ample amounts of data have proved such effects in mice.^{34–38} A distinct mechanism for transmission of IR effects to offspring is thought to underlie the difference between humans and rodents. The results of Sorokina et al. suggest a transgenerational transmission of RAR signals in mice, which should provide an insight into the mechanisms behind the frequently observable genetic effects in this species. More studies into the mechanism of transgenerational transmission of RAR signals are required.

Human data

RAR was first discovered by analyzing X-ray-induced chromatid aberrations in cultured lymphocytes obtained from the peripheral blood of healthy human adults.¹ Subsequently, a number of *in vitro* studies were conducted to investigate the characteristics and mechanisms of RAR in human lymphocytes.² In accord with these *in vitro* studies, data have been obtained for human *in vivo* RAR after long-term low-dose-rate exposure to environmental, occupational, and accidental radiation as previously summarized by Tapio and Jacob.³ For instance, Ghiassi-nejad et al.³⁹ analyzed chromosomal aberrations in lymphocytes collected from residents in a high background radiation area (HBRA) and normal background radiation area in Ramsar, Iran. Residents in the HBRA had been exposed to up to 260 mGy year⁻¹ primarily due to high concentrations of radium-226 on the ground. When the lymphocytes collected from residents in the HBRA were exposed to 1.5 Gy of γ rays, a

significantly lower frequency of chromosomal aberration was observed compared with that in 1.5 Gy-irradiated lymphocytes collected from the normal background radiation area residents. This result suggests that long-term exposure of human individuals to low-dose-rate IR induces a steady radioresistance. A potential criticism against the interpretation of the radioresistance in HBRA residents as a result of RAR is that radioresistant individuals may have been selected during stable inhabitation over multiple generations. However, sensitivity to the low-dose-rate IR from natural sources is unlikely subjected to natural selection because the effects would appear much later than reproductive age. A more sound analysis is required into the possible correlation of the radioresistance in HBRA residents with any advantageous genetic changes.

As another example, Barquinero et al.⁴⁰ studied RAR in lymphocytes after *in vivo* exposure to medical IR. The chromosomal aberration induced by challenge irradiation with 2 Gy of X-rays in lymphocytes collected from hospital workers who had been exposed to IR of up to 28 mSv year⁻¹ was significantly lower than that in lymphocytes taken from nonradiation workers. A common shortcoming of these and other human RAR studies is that the number of donors who provided the blood sample was limited. As a result, significance of the data was often limited by poor statistical power due to large interindividual variations in both basal IR sensitivity and RAR inducibility. However, the influence of the interindividual variation in basal IR sensitivity was thought to be eliminated by measuring IR sensitivity of lymphocytes taken from identical individuals both before and after exposure to priming low-dose-rate IR. Based on this strategy, the micronuclei induction by 3.5 Gy of γ rays was tested in short-term radiation workers who had been exposed to 3 mSv on average in about 5 weeks by Thierens et al.¹⁴ Blood samples were collected twice before and after the radiation work, and it was found that for the majority of the workers, micronuclei induction by 3.5 Gy of γ rays was lower in lymphocytes collected after radiation work.

Mechanisms for *in vivo* RAR

Protective bystander effects. It is widely believed that the initial event for RAR is the generation of DSB,³⁵ although there are some exceptions that suggest RAR is triggered by nongenotoxic agents such as radiofrequency fields.^{15,41} Initiated by a few DSB per cell, signal transduction cascades involving *de novo* protein synthesis are elicited⁴² and are thought to result




Figure 1. Signal transduction functioning in RAR. RAR: radioadaptive response; DSB: double-strand break; iNOS: inducible nitric oxide synthase; PKC: protein kinase C; PLC: phospholipase C; NO: nitric oxide; ROS: reactive oxygen species; MAPK: mitogen-activated protein kinase. Modified from Nenoi et al.⁷² with permission of Radiation Biology Research Communications.

in activation of effector factors that play direct roles either in enhancement of DNA repair, induction of molecular chaperon, synchronization of the cell cycle, or induction of antioxidants.⁴³ The signaling factor p53 is crucial in various experimental systems for RAR.² *In vitro* studies revealed that RAR is a transient but quasi-sustainable response in which radioresistance is typically elevated during a limited time period of about 20 h following a time interval of about 4 h after priming irradiation.⁴⁴ Shimizu et al.⁴⁵ and Sasaki et al.⁴⁴ proposed a model of a molecular mechanism for RAR emphasizing a pivotal role of signaling factors as shown in Figure 1. Here, in response to a small number of DSB produced by a priming dose in the cell nucleus, a long-lasting signal transduction circuit circulating between cell nucleus and cell membrane is postulated, which would be maintained by p38 mitogen-activated protein kinases, phospholipase C, and protein kinase C (PKC). The RAR signal is thought to be transferred to neighboring cells through growth factors, reactive oxygen species, and/or nitric oxide (NO), which bring about protective bystander effects.

The IR-induced bystander response was originally characterized by the cellular effects expressed in unirradiated cells located in some vicinity to an irradiated cell or cells.⁴⁶ It was initially described in 1992 by Nagasawa and Little,⁴⁷ who observed an elevated frequency (20–40%) of sister chromatid exchanges in Chinese hamster ovary cells in the condition where

only 0.1-1% of cell nuclei were actually traversed by an α -particle track. The bystander effect is mediated by two modes of signal transduction from irradiated cells to unirradiated bystander cells; one is transmission of signaling molecules through a gap junction assembly spanning plasma membranes of adjacent two cells, and the other is interaction of factors secreted from irradiated cells with their specific receptors in bystander cells. It was recently reported that RAR is induced via the bystander mechanism (referred to as protective bystander effects). By measuring DSB in primary normal human fibroblast MRC-5 cells irradiated with 1 Gy of X-rays, Ojima et al.⁴⁸ observed that the mean number of DSB per cell significantly decreased when nondividing confluent cells were preirradiated with 3–5 mGy of X-rays 4 h prior to the challenge irradiation. The authors further found that the effect of the preirradiation was diminished when the cells were incubated with lindane, an inhibitor of gap junction assembly, for 2 h before the priming irradiation. The result clearly indicated that the RAR was induced depending on signaling molecules transmitted through the gap junction. By investigating RAR with the end point of chromosomal aberrations in human H1299 lung cancer cells, Takahashi et al.⁴⁹ observed that the RAR was blocked by aminoguanidine, an inducible NO synthase inhibitor, or 2-(4-Carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl-3-oxide (carboxy PTIO), an NO radical scavenger. The authors further observed that an RAR-like response was induced by treatment of cells with isosorbide dinitrate, an NO-generating agent, alone. On the basis of these observations, they concluded that RAR was induced via NO radicals as intercellular signaling mediators. In addition, by incubating mouse embryonic fibroblasts in the media transferred from the replica culture irradiated with 0.1–1 Gy of X-rays, Klammer et al.⁵⁰ found that the activity of DNA-PKc-dependent nonhomologous end joining was slightly but significantly elevated in unirradiated cells with similar kinetics compared with directly irradiated cells. Although the mechanisms are yet to be determined, involvement of enhanced DSB repair activity in protective bystander effects could be suggested.

RAR is a cellular response whereby radioresistance is elevated only during a limited time period after priming irradiation. However, it may be expected that radioresistance is sustainably induced by IR at an extremely low-dose rate (a few DSB or less in 1 year) considering the role of bystander effects in RAR. This can be depicted by a simplified and hypothetical model of in vivo RAR illustrated in Figure 2. The

model is based on three assumptions, which were derived from in vitro studies: (1) RAR is initiated by a DSB, and the resistance to subsequent DSB is induced in cells during a limited time period of 4–24 h after generation of initial DSB as shown in Figure 2(a); (2) during the time period in which resistance to DSB is induced, the RAR signal is also transmitted to neighboring cells (up to N th cells) in all directions from the cell in which the initial DSB was generated (Figure 2(b)); and (3) the cells can repeatedly become radioresistant as long as they receive the RAR signal. On the basis of these assumptions, every cell in the three-dimensional structure can receive an RAR signal from its neighboring $(2N + 1)^3$ cells as shown by the gray cube in Figure 2(b). When the dose rate and number of DSB produced by 1 Gy are represented by R (in gray per hour) and λ (per gray), respectively, the probability that radioresistance is induced in each cell, P , can be described as:

$$P = 1 - (1 - 20\lambda R)^M,$$

where $M = (2N + 1)^3$.

The yield of DSB induced by IR in a cell was found to be linearly dependent on dose with a rate of approximately 30 Gy^{-1} ($\lambda = 30 \text{ Gy}^{-1}$).^{51,52} The propagation distance has been reported to vary in the range of 0.1–3 mm, roughly corresponding to >3 cells.⁵³ However, no data are available to date on the transmission of protective bystander signals. If we postulate that the protective bystander RAR signal could be transmitted up to a third of the neighboring cells ($N = 3$) and a dose rate of 3 mSv in 5 weeks ($R = 3.4 \times 10^{-6} \text{ Gy h}^{-1}$) is used as an example, we obtain $P = 0.50$.

This calculation suggests that resistance to DSB is induced in 50% of cells as long as irradiation is continued, and therefore, the induced radioresistance would likely be experimentally detectable. Thus, it is suggested that the cancer incidence after low-dose-rate IR could be reduced by an RAR mediated by the protective bystander effect. However, it should be noted that the outcome of RAR by low-dose-rate IR would be a persistent elevation of radioresistance, which would be indistinguishable from the general dose rate effects.

Potential association of endocrine factors. In vivo RAR can be regarded as a type of homeostatic control, where constancy in the internal environment of the body is maintained by various sensing, feedback, and control mechanisms. Because the endocrine response is a key mechanism for homeostatic control, regulation through endocrine factors is also a plausible




Figure 2. A hypothetical model for in vivo RAR depending on intercellular communication via gap junction. (a) It is postulated that the resistance to DNA DSBs is induced in cells during a limited time period of 4–24 h after generation of the initial DSB (indicated by a horizontally long oval), and (b) it is also postulated that the RAR signal is transmitted to neighboring cells (up to the N th cells) in all directions from the cell in which the initial DSB was generated. It is also postulated that the cells can become radioresistant repeatedly as long as they receive the RAR signal. (c) Based on these assumptions, cells in the three-dimensional structure can receive multiple RAR signals from neighboring cells. RAR: radioadaptive response; DSB: double-strand break. Modified from Nenoi et al.⁷³ with permission of National Institute of Radiological Sciences.

mechanism for RAR at the individual level. The release of glucocorticoids (cortisol in humans, rabbits, and squirrels or corticosterone in mice and rats) from the adrenal cortex is a typical response of vertebrates to stressors such as intrinsic ROS and extrinsic assaults including infectious agents, toxic substances, and temperature extremes.^{54,55} The major role of glucocorticoid is to protect individuals against the excessive actions of immune and inflammatory responses. However, it was shown that glucocorticoids play a role in mitigating the harmful effects of a variety of stressors⁵⁶ and moderate hyperadrenocorticism (increased secretion of glucocorticoids) induced by low levels of stressors making individuals resistant to these stressors. By

examining blood samples collected from Chernobyl workers who carried out cleanup operations at the destroyed reactor from 1986 to 1988 (approximately 120 mSv of exposure on average over 1–3 months), Souchkevitch and Lyasko⁵⁷ revealed a statistically significant increase in cortisol level compared with the controls. Similarly, Boonstra et al.⁵⁸ reported a significantly higher level of corticosterone in meadow voles irradiated with low-dose-rate γ rays ($22.6 \mu\text{Gy h}^{-1}$ over 2.5 years) than those in the control or higher dose-rate ($3840 \mu\text{Gy h}^{-1}$ over 1.5 years)-irradiated groups. These results suggest a potential role of glucocorticoids in RAR induced in vivo after a long-term low-dose-rate exposure to IR.

In a normal condition, glucocorticoid receptor (GR) remains in the cytoplasm in large macromolecular complexes bound to chaperones such as HSP90. Upon ligand binding, GR dissociates from the complex and translocates into the cell nucleus where it activates or represses transcription of various genes depending on physiological conditions.^{59–61} Vares et al.⁶² searched for potential recognition sequences for transcription factors in the upstream region of the genes whose expression was modulated in the liver of C57BL/6J mice after long-term (400 days) irradiation at low dose rates (2.3–910 $\mu\text{Gy h}^{-1}$). As a result, the potential recognition sequence for GR was found with a significantly higher frequency than that in unmodulated genes consistent with the observations that the glucocorticoid level was modulated after a low-dose-rate irradiation. This result further supports the idea that glucocorticoids may be involved in in vivo RAR after low-dose-rate IR. However, the level of the dose response of GR and glucocorticoids after exposure to IR seems complicated, as Liu⁶³ has shown a decreased GR level in splenic T cells after a low-dose (30–75 mGy) X-irradiation. It is also elusive whether activated GR suppresses IR carcinogenesis. Whereas p53 is a key factor in the suppression of carcinogenesis after exposure to IR, GR is known to interact with p53 in both a complementary and antagonistic fashion depending on physiological and pathological conditions.⁶⁴ The physical interaction of GR and p53 in the presence of ligand causes their cytoplasmic sequestration and degradation through the proteasome pathway by recruiting the E3 ubiquitin ligase Hdm2, resulting in inhibition of each other's transactivation properties.^{65–67} Consistently, it was reported that a short-term in vitro exposure of BALB/c 3T3 cells to physiological concentrations of cortisol consistently resulted in increased DNA damage and cellular transformation.⁶⁸ In addition, using a p53 heterozygous mouse model with an elevated corticosterone level due to chronic restraint stress, Feng et al.⁶⁹ demonstrated that the carcinogenic effect of IR was enhanced through reduced p53 activity. These observations suggest an enhancement of the carcinogenic effects of IR by glucocorticoids. In contrast, it was demonstrated that activated GR caused translocation of p53 to the cell nucleus, leading to enhanced transcription of p53-target genes.⁷⁰ GR was also found to stimulate p21 gene transcription through the steroid response element in the promoter in rat hepatoma cells.⁷¹ More studies are required to clarify how glucocorticoids modulate cancer susceptibility depending on physiological and pathological conditions.

Conclusion

Carcinogenic RAR has been demonstrated in various strains of mice, and the majority of in vivo RAR studies revealed efficient induction of RAR by chronic or repeated low-dose priming irradiation. In vivo RAR in humans after long-term low-dose-rate exposure to environmental, occupational, and nuclear accident IR was also reported. The recent finding of protective bystander effects via gap junction-mediated intercellular signal transduction suggests that exposure of only a small fraction of cells to IR could induce RAR at the individual level, providing insights into the mechanism for in vivo RAR after very low-dose-rate exposure. In addition, by viewing RAR as a type of homeostatic control, regulation through endocrine factors is thought to be a plausible mechanism for RAR at the individual level. Emerging evidence suggests that glucocorticoids, known as stress hormones, are involved in in vivo RAR after long-term low-dose-rate exposure to IR. In vivo RAR induced by exposure to low-dose-rate IR should be reflected in the reduced effects of the low-dose-rate IR itself, and this effect should be indistinguishable from the general dose rate effects. Thus, in vivo RAR induced by low-dose-rate IR does not seem to have a drastic effect on the conventional radiation protection system. However, to establish a scientific basis for estimation and control of the IR sensitivity of individuals as an essential factor for prospective tailor-made radiation protection, more in vivo studies as well as studies of the underlying mechanism are necessary, with a particular focus on genetic components associated with interindividual differences of RAR.

Conflict of interest

The authors declared no conflicts of interest.

Funding

This work was partially supported by JSPS KAKENHI 25340041.

References

1. Olivieri G, Bodycote J, and Wolff S. Adaptive response of human lymphocytes to low concentrations of radioactive thymidine. *Science* 1984; 223: 594–597.
2. Vares G, Wang B, Tanaka K, et al. Radiation-induced adaptive response with reference to evidence and significance: a review. *Indian J Rad Res* 2006; 3: 16–34.
3. Tapio S and Jacob V. Radioadaptive response revisited. *Radiat Environ Biophys* 2006; 46: 1–12.

4. Kalina I and Némethová G. Variability of the adaptive response to low dose radiation in peripheral blood lymphocytes of twins and unrelated donors. *Folia Biol (Praha)* 1997; 43: 91–95.
5. International Commission on Radiation Protection (ICRP). Low-dose extrapolation of radiation-related cancer risk. Publication 99, *Annals of the ICRP* 2005; 35(4): 1–142.
6. Matsumoto H, Hamada N, Takahashi A, et al. Vanguard of paradigm shift in radiation biology: radiation-induced adaptive and bystander responses. *J Rad Res* 2007; 48: 97–106.
7. Matsumoto H, Tomita M, Otsuka K, et al. A new paradigm in radioadaptive response developing from microbeam research. *J Radiat Res* 2009; 50(Suppl A): A67–A79.
8. Mitchel RE. Low doses of radiation are protective in vitro and in vivo: evolutionary origins. *Dose Response* 2006; 4: 75–90.
9. Mitchel RE. Low doses of radiation reduce risk in vivo. *Dose Response* 2006; 5: 1–10.
10. Bhattacharjee D. Role of radioadaptation on radiation-induced thymic lymphoma in mice. *Mut Res* 1996; 358: 231–235.
11. Ina Y, Tanooka H, Yamada T, et al. Suppression of thymic lymphoma induction by life-long low-dose-rate irradiation accompanied by immune activation in C57BL/6 mice. *Radiat Res* 2005; 163: 153–158.
12. Mitchel RE, Jackson JS, McCann RA, et al. The adaptive response modifies latency for radiation-induced myeloid leukemia in CBA/H mice. *Radiat Res* 1999; 152: 273–279.
13. Kakinuma S, Yamauchi K, Amasaki Y, et al. Low-dose radiation attenuates chemical mutagenesis in vivo. *J Radiat Res* 2009; 50: 401–405.
14. Thierens H, Vral A, Barbé M, et al. Chromosomal radiosensitivity study of temporary nuclear workers and the support of the adaptive response induced by occupational exposure. *Int J Radiat Biol* 2002; 78: 1117–1126.
15. Jiang B, et al. Adaptive response in mice exposed to 900 MHz radiofrequency fields: primary DNA damage. *PLoS One* 2012; 7: e32040.
16. Ikeda M, Masumura K, Sakamoto Y, et al. Combined genotoxic effects of radiation and a tobacco-specific nitrosamine in the lung of gpt delta transgenic mice. *Mutat Res* 2007; 626: 15–25.
17. Liu SZ, Cai L, and Sun SQ. Induction of a cytogenetic adaptive response by exposure of rabbits to very low dose-rate gamma radiation. *Int J Radiat Biol* 1992; 62: 187–190.
18. Cai L and Liu SZ. Induction of cytogenetic adaptive response of somatic and germ cells in vivo and in vitro by low-dose X-irradiation. *Int J Radiat Biol* 1990; 58: 187–194.
19. Mosse L, Kostrova I, Subbot S, et al. Melanin decreases clastogenic effects of ionizing radiation in human and mouse somatic cells and modifies the radioadaptive response. *Radiat Environ Biophys* 2000; 39: 47–52.
20. Kind JA, Winn RN, Boerrigter ME, et al. Investigation of the radioadaptive response in brain and liver of pUR288 lacZ transgenic mice. *J Toxicol Environ Health, A* 2001; 63: 207–220.
21. Day TK, Zeng G, Hooker AM, et al. Extremely low priming doses of X radiation induce an adaptive response for chromosomal inversions in pKZ1 mouse prostate. *Radiat Res* 2006; 166: 757–766.
22. Otsuka K, Koana T, Tauchi H, et al. Activation of antioxidative enzymes induced by low-dose-rate whole-body gamma irradiation: adaptive response in terms of initial DNA damage. *Radiat Res* 2006; 166: 474–478.
23. Wang B, Tanaka K, Ninomiya Y, et al. Relieved residual damage in the hematopoietic system of mice rescued by radiation-induced adaptive response (Yonezawa Effect). *J Radiat Res* 2013; 54: 45–51.
24. Phan N, De Lisio M, Parise G, et al. Biological effects and adaptive response from single and repeated computed tomography scans in reticulocytes and bone marrow of C57BL/6 mice. *Radiat Res* 2012; 177: 164–175.
25. Howell EK, Gaschak SP, Griffith KD, et al. Radioadaptive response following in utero low-dose irradiation. *Radiat Res* 2013; 179: 29–37.
26. Escribano-Díaz C, Orthwein A, Fradet-Turcotte A, et al. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. *Mol Cell* 2013; 49: 872–883.
27. Mitchel RE, Jackson JS, Morrison DP, et al. Low doses of radiation increase the latency of spontaneous lymphomas and spinal osteosarcomas in cancer-prone, radiation-sensitive Trp53 heterozygous mice. *Radiat Res* 2003; 159: 320–327.
28. Shadley JD and Wiencke JK. Induction of the adaptive response by X-rays is dependent on radiation intensity. *Int J Radiat Biol* 1989; 56: 107–118.
29. Wiencke JK, Afzal V, Olivieri G, et al. Evidence that the [3H]thymidine-induced adaptive response of human lymphocytes to subsequent doses of X-rays involves the induction of a chromosomal repair mechanism. *Mutagenesis* 1986; 1: 375–380.
30. Kleczkowska HE and Althaus FR. The role of poly (ADP-ribosyl)ation in the adaptive response. *Mutat Res* 1996; 358: 215–221.

31. Varès G, Wang B, Tanaka K, et al. Mutagenic adaptive response to high-LET radiation in human lymphoblastoid cells exposed to X-rays. *Mutat Res* 2011; 706: 46–52.
32. Varès G, Wang B, Tanaka K, et al. Mutagenic adaptive response to high-LET radiation in human lymphoblastoid cells exposed to low doses of heavy-ion radiation. *Mutat Res* 2011; 712: 49–54.
33. Sorokina SS, Zaichkina SI, Rozanova OM, et al. Delayed effects of chronic low-dose high linear energy transfer (LET) radiation on mice in vivo. *Radiat Prot Dosim* 2011; 143: 305–310.
34. Russell WL and Kelly EM. Mutation frequencies in male mice and the estimation of genetic hazards of radiation in men. *Proc Nat Acad Sci U S A* 1982; 79: 542–544.
35. Pomerantseva MD, Goloshchapov PV, Vilkina GA, et al. Genetic effect of chronic exposure of male mice to gamma rays. *Mutat Res* 1984; 141: 195–200.
36. Dubrova YE and Plumb MA. Ionising radiation and mutation induction at mouse minisatellite loci. The story of the two generations. *Mutat Res* 2002; 499: 143–150.
37. Wu J, Morimyo M, Hongo E, et al. Radiation-induced germline mutations detected by a direct comparison of parents and first-generation offspring DNA sequences containing SNPs. *Mutat Res* 2006; 596: 1–11.
38. Nomura T. Transgenerational effects of radiation and chemicals in mice and humans. *J Radiat Res* 2006; 47(Suppl B): B83–B97.
39. Ghiassi-nejad M, Mortazavi SM, Cameron JR, et al. Very high background radiation areas of Ramsar, Iran: preliminary biological studies. *Health Phys* 2002; 82: 87–93.
40. Barquinero JF, Barrios L, Caballín MR, et al. Occupational exposure to radiation induces an adaptive response in human lymphocytes. *Int J Radiat Biol* 1995; 67: 187–191.
41. Jiang B, Nie J, Zhou Z, et al. Induction of adaptive response in mice exposed to 900MHz radiofrequency fields: application of micronucleus assay. *Mutat Res* 2013; 751: 127–129.
42. Youngblom JH, Wiencke JK, and Wolff S. Inhibition of the adaptive response of human lymphocytes to very low doses of ionizing radiation by the protein synthesis inhibitor cycloheximide. *Mutat Res* 1989; 227: 257–261.
43. Coleman MA, Yin E, Peterson LE, et al. Low-dose irradiation alters the transcript profiles of human lymphoblastoid cells including genes associated with cytogenetic radioadaptive response. *Radiat Res* 2005; 164: 369–382.
44. Sasaki MS, Ejima Y, Tachibanà A, et al. DNA damage response pathway in radioadaptive response. *Mutat Res* 2002; 504: 101–118.
45. Shimizu T, Kato T Jr, Tachibana A, et al. Coordinated regulation of radioadaptive response by protein kinase C and p38 mitogen-activated protein kinase. *Exp Cell Res* 1999; 251: 424–432.
46. Kadhim M, Salomaa S, Wright E, et al. Non-targeted effects of ionising radiation—Implications for low dose risk. *Mutat Res* 2013; 752: 84–98.
47. Nagasawa H and Little JB. Induction of sister chromatid exchanges by extremely low doses of alpha-particles. *Canc Res* 1992; 52: 6394–6396.
48. Ojima M, Eto H, Ban N, et al. Radiation-induced bystander effects induce radioadaptive response by low-dose radiation. *Radiat Prot Dosim* 2011; 146: 276–279.
49. Takahashi A, Matsumoto H, and Ohnishi T. Hdm2 and nitric oxide radicals contribute to the p53-dependent radioadaptive response. *Int J Rad Oncol, Biol, Phys* 2008; 71: 550–558.
50. Klammer H, Kadhim M, and Iliakis G. Evidence of an adaptive response targeting DNA nonhomologous end joining and its transmission to bystander cells. *Canc Res* 2010; 70: 8498–8506.
51. Löbrich M, Ikpeme S, and Kiefer J. Measurement of DNA double-strand breaks in mammalian cells by pulsed-field gel electrophoresis: a new approach using rarely cutting restriction enzymes. *Radiat Res* 1994; 138: 186–192.
52. Löbrich M, Ikpeme S, and Kiefer J. DNA double-strand break measurement in mammalian cells by pulsed-field gel electrophoresis: an approach using restriction enzymes and gene probing. *Int J Radiat Biol* 1994; 65: 623–630.
53. Hamada N, Maeda M, Otsuka K, et al. Signaling pathways underpinning the manifestations of ionizing radiation-induced bystander effects. *Curr Mol Pharmacol* 2011; 4: 79–95.
54. Masoro EJ. Hormesis and the antiaging action of dietary restriction. *Exp Gerontol* 1998; 33: 61–66.
55. Masoro EJ. Caloric restriction and aging: an update. *Exp Gerontol* 2000; 35: 299–305.
56. Munck A, Guyre PM, and Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. *Endocr Rev* 1984; 5: 25–44.
57. Souchkevitch G and Lyasko L. Investigation of the impact of radiation dose on hormones, biologically active metabolites and immunoglobulins in Chernobyl accident recovery workers. *Stem Cells* 1997; 15(Suppl 2): 151–154.

58. Boonstra R, Manzon RG, Mihok S, et al. Hormetic effects of gamma radiation on the stress axis of natural populations of meadow voles (*Microtus pennsylvanicus*). *Environ Toxicol Chem* 2005; 24: 334–343.
59. Tronche F, Kellendonk C, Reichardt HM, et al. Genetic dissection of glucocorticoid receptor function in mice. *Curr Opin Genet Dev* 1998; 8: 532–538.
60. Reichardt HM and Schütz G. Glucocorticoid signaling—multiple variations of a common theme. *Mol Cell Endocrinol* 1998; 146: 1–6.
61. Kellendonk C, Tronche F, Reichardt HM, et al. Mutagenesis of the glucocorticoid receptor in mice. *J Steroid Biochem Mol Biol* 1999; 69: 253–259.
62. Vares G, Uehara Y, Ono T, et al. Transcription factor-recognition sequences potentially involved in modulation of gene expression after exposure to low-dose-rate γ -rays in the mouse liver. *J Radiat Res* 2011; 52: 249–256.
63. Liu SZ. Radiation-induced change in lymphocyte proliferation and its neuroendocrine regulation: dose-response relationship and pathophysiological implications. *Nonlinearity Biol, Toxicol, Med* 2004; 2: 233–243.
64. Sengupta S and Wasylyk B. Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors. *Ann NY Acad Sci* 2004; 1024: 54–71.
65. Sengupta S, Vonesch JL, Waltzinger C, et al. Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. *EMBO J* 2000; 19: 6051–6064.
66. Maiyar AC, Phu PT, Huang AJ, et al. Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein. *Mol Endocrinol* 1997; 11: 312–329.
67. Sengupta S and Wasylyk B. Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. *Genes Dev* 2001; 15: 2367–2380.
68. Flint MS, Baum A, Chambers WH, et al. Induction of DNA damage, alteration of DNA repair and transcriptional activation by stress hormones. *Psychoneuroendocrinology* 2007; 32: 470–479.
69. Feng Z, Liu L, Zhang C, et al. Chronic restraint stress attenuates p53 function and promotes tumorigenesis. *Proc Nat Acad Sci U S A* 2012; 109: 7013–7018.
70. Crochemore C, Michaelidis TM, Fischer D, et al. Enhancement of p53 activity and inhibition of neural cell proliferation by glucocorticoid receptor activation. *FASEB J* 2002; 16: 761–770.
71. Cha HH, Cram EJ, Wang EC, et al. Glucocorticoids stimulate p21 gene expression by targeting multiple transcriptional elements within a steroid responsive region of the p21waf1/cip1 promoter in rat hepatoma cells. *J Biol Chem* 1998; 273: 1998–2007.
72. Nenoi M, Vares G, and Wang B. Multiple factors involved in expression of radioadaptive responses (in Japanese). *Radiat Biol Res Commun* 2009; 44: 294–311.
73. Nenoi M. Future challenges of low-dose radiation research (in Japanese). *Radiol Sci* 2012; 55: 35–36.